In my second article for GEN magazine on regenerative medicine I’ve focused on cost of goods. Without complete devices or systems that are designed and manufactured with cost and manufacturability in mind, the scientists behind some truly ground-breaking regenerative therapies or interventions may never see their creations reach the market or obtain the investment they need to develop it further.
We’ve always argued the case for considering device design from the outset, not once the science is finalised as the therapy and the enabling device need to co-exist. In my article I’ve focused on why this is so important, especially in the embryonic RegenMed sector. You can download a copy of my article here.
Alternatively you can read it via SlideShare below:
View more documents from Team Consulting Ltd
Looking for industry insights? Click below to get our opinions and thoughts into the world of medical devices and healthcare.
